Histogen Announces Preliminary Week 18 HST-001 Study Results For Treatment Of Androgenic Alopecia In Men; Says HST-001 Demonstrated Separation From Placebo At Week 18 Primary Efficacy Endpoint Assessment, No Serious Adverse Events

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!